Scholar Rock
- Market cap
- 5.14B
- P/E (TTM)i
- -12.75
- P/Bi
- 20.25
- EPSi
- -3.29
- Div yieldi
- 0.00%
- 52W posi
- 44%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Scholar Rock (SRRK) | 5.14B | -12.75 | 20.25 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 128.16B | 29.45 | 6.33 | 0.00% |
| Moderna (MRNA) | 78.44B | -24.62 | 11.60 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 76.40B | 18.36 | 2.41 | 0.49% |
| argenx SE (ARGX) | 58.39B | 35.37 | 6.94 | 0.00% |
| Revolution Medicines (RVMD) | 43.05B | -22.65 | 16.52 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 59.8% below Morningstar's fair value estimate.
Fair value
Scholar Rock Holding Corp receives a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 35% discount to our quantitative fair value estimate of $67.42 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's balance sheet increases our quantitative valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 7.0 sits in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.
The firm's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 1.0, for example, falls in the bottom 40% compared with peers globally. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. This characteristic further promotes our favorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-08 05:47:26 · For reference only, not investment advice and not tailored to your situation.